User profiles for Dermot O'Callaghan

Dermot O'Callaghan

Verified email at mater.ie
Cited by 4449

Pulmonary arterial hypertension in patients treated by dasatinib

…, D Natali, C Guignabert, F Perros, DS O'Callaghan… - Circulation, 2012 - Am Heart Assoc
Background— The French pulmonary hypertension (PH) registry allows the survey of
epidemiological trends. Isolated cases of precapillary PH have been reported in patients who have …

[HTML][HTML] A hemodynamic study of pulmonary hypertension in sickle cell disease

…, A Yaïci, L Hajji, DS O'Callaghan… - … England Journal of …, 2011 - Mass Medical Soc
Background The prevalence and characteristics of pulmonary hypertension in adults with
sickle cell disease have not been clearly established. Methods In this prospective study, we …

[HTML][HTML] The role of inflammation in the pathogenesis of non-small cell lung cancer

DS O'Callaghan, D O'Donnell, F O'Connell… - Journal of thoracic …, 2010 - Elsevier
The link between chronic immune activation and tumorigenesis is well established. Compelling
evidence has accumulated that histologic assessment of infiltration patterns of different …

Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an ACVRL1 (ALK1) Mutation

…, A Fraisse, O Sitbon, DS O'Callaghan… - American journal of …, 2010 - atsjournals.org
Rationale: Activin A receptor type II-like kinase-1 (ACVRL1, also known as ALK1) mutation is
a cause of hereditary hemorrhagic telangiectasia (HHT) and/or heritable pulmonary arterial …

A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma

…, F de Blay, LJ Couderc, A Didier, DS O'Callaghan… - Chest, 2013 - Elsevier
Background While up to 50% of patients with severe asthma have no evidence of allergy,
IgE has been linked to asthma, irrespective of atopic status. Omalizumab, an anti-IgE …

Treatment of pulmonary arterial hypertension with targeted therapies

DS O'callaghan, L Savale, D Montani, X Jaïs… - Nature Reviews …, 2011 - nature.com
Pulmonary arterial hypertension (PAH) is a rare disorder characterized by progressive
obliteration of the pulmonary microvasculature that results in elevated pulmonary vascular …

Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study

K Kemp, L Savale, DS O'Callaghan, X Jaïs… - The Journal of heart and …, 2012 - Elsevier
BACKGROUND: Recent guidelines have proposed first-line combination therapy as a
potential strategy for the treatment of functional class IV pulmonary arterial hypertension (PAH). …

Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension

…, X Jaïs, D Montani, DS O'Callaghan… - European …, 2013 - Eur Respiratory Soc
Data on treatment of patients with portopulmonary hypertension (PoPH) are limited, as they
are usually excluded from randomised controlled trials with pulmonary arterial hypertension (…

[HTML][HTML] Pulmonary veno-occlusive disease: recent progress and current challenges

D Montani, DS O'Callaghan, L Savale, X Jaïs… - Respiratory …, 2010 - Elsevier
Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pulmonary arterial
hypertension characterised by a progressive obstruction of small pulmonary veins that leads to …

Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer

DS O'Callaghan, E Rexhepaj, K Gately… - European …, 2015 - Eur Respiratory Soc
The impact of host immunity on outcome in nonsmall cell lung cancer (NSCLC) is controversial.
We examined the relationship between lymphoid infiltration patterns in NSCLC and …